Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Biotechnol Appl Biochem ; 69(4): 1733-1740, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34423464

RESUMEN

Osteosarcoma is a commonly occurring bone malignancy, and it is the second most common cause of cancer deaths in adolescents and children. A sensitive silica nanoparticle (Si-NP) modified current-volt sensor was introduced to identify the osteopontin antigen, a well-known biomarker for osteosarcoma. Si-NP was extracted from the rice husk ash and utilized for the surface functionalization on the interdigitated microelectrode sensing surface. Extracted Si-NP has a spherical shape with uniform distribution, and it is confirmed by field emission scanning electron microscopy and field-emission transmission electron microscopy. Si-NP was layered on the electrode surface through a (3-aminopropyl)triethoxysilane amine linker, and the antibody was immobilized on Si-NP through a glutaraldehyde linker. Osteopontin was effectively detected on the antibody-attached surface, and the determination limit was 0.6 ng/mL. The regression was determined as y = 0.9366x - 1.1113 and the R2 value was 0.9331 and the detection limit of osteopontin was 0.6 ng/mL in the range between 0.3 and 5 ng/mL. In addition, control performance with nonimmune antibodies and albumin did not change the current volt, showing the specific osteopontin identification. This research work brings out the easy and cost-effective method to diagnose osteosarcoma and its etiology.


Asunto(s)
Nanopartículas , Osteosarcoma , Adolescente , Anticuerpos , Niño , Electrodos , Humanos , Límite de Detección , Osteopontina , Osteosarcoma/diagnóstico , Dióxido de Silicio
2.
Clin Interv Aging ; 10: 803-11, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25960644

RESUMEN

BACKGROUND: Intramedullary and extramedullary fixation methods are used in the management of subtrochanteric femur fractures. However, whether intramedullary or extramedullary fixation is the primary treatment for subtrochanteric femur fractures in adults remains debatable. LEVEL OF EVIDENCE: Meta-analyses of prospective studies, level I. MATERIALS AND METHODS: The Cochrane library, Embase, Google Scholar, and PubMed databases were searched separately for all relevant studies published before January 1, 2015. No language restriction was applied. Prospective randomized controlled trials that compared intramedullary or extramedullary internal fixation to repair subtrochanteric femur fractures in adults were included. We determined intraoperative data, postoperative complications, fracture fixation complications, wound infection, hospital stay days, and final outcome measures to assess the relative effects of different internal fixation methods for the treatment of subtrochanteric femur fractures in adults. RESULTS: Six studies were included in our meta-analysis. The relative risks (RRs) of revision rate was 83% lower (RR, 0.17, 95% confidence interval [CI], 0.05 to 0.60; P=0.006), fixation failure rate was 64% lower (RR, 0.36, 95% CI, 0.12 to 1.08; P=0.07), non-union rate was 77% lower (RR, 0.23, 95% CI, 0.07 to 0.81; P=0.02) in the intramedullary group compared with the extramedullary group. No significant differences were found between the intramedullary group and extramedullary group for intraoperative data, postoperative complications, wound infection, hospital stay days or final outcome measures. CONCLUSION: In conclusion, our meta-analysis suggests that there was no significant difference in intraoperative data, postoperative complications, wound infection, hospital stay days or final outcome measures between intramedullary and extramedullary internal fixation. However, a significant decrease occurred in the rate of fracture fixation complications for patients treated with intramedullary internal fixation, especially in elderly patients. Some differences were not significant, but the treatment of elderly subtrochanteric femur fractures using intramedullary internal fixation is recommended.


Asunto(s)
Fijación Interna de Fracturas/métodos , Fracturas de Cadera/cirugía , Complicaciones Posoperatorias/epidemiología , Fémur , Fijación Intramedular de Fracturas/métodos , Humanos , Complicaciones Intraoperatorias/epidemiología , Tiempo de Internación , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto , Reoperación , Resultado del Tratamiento
3.
Med Sci Monit ; 21: 90-3, 2015 Jan 08.
Artículo en Inglés | MEDLINE | ID: mdl-25567738

RESUMEN

BACKGROUND: The aim of this study was to compare radial head prosthesis replacement with open reduction and internal fixation (ORIF) in the surgical treatment of Mason type III radial head fractures in 72 elderly patients. MATERIAL/METHODS: Seventy-two elderly patients (mean age, 67.1±1.25 years, range, 62-81 years) with Mason type III radial head fractures were treated from January 2001 to June 2012. Of these, 37 cases received radial prosthesis and 35 cases were treated with ORIF. All patients were followed up for 10 to 15.6 months. RESULTS: Based on the elbow functional evaluation criteria score by Broberg and Morrey, 29 cases achieved excellent results, 7 were good, and 1 was fair in the replacement group. In the ORIF group, excellent results were seen in 24 cases, good in 9, and fair in 2. The rates of good or excellent results were 78.4% and 68.6% for prosthesis replacement patients and ORIF patients, respectively (P<0.05). The Visual Analogue Scores (VAS) for replacement and ORIF groups were 2.25 and 1.67, respectively (P<0.05). CONCLUSIONS: The radial head prosthesis replacement method is a relatively better surgical approach than ORIF in the treatment of elderly patients with Mason type III radial head fractures.


Asunto(s)
Fijación Interna de Fracturas/métodos , Fracturas del Radio/cirugía , Anciano , Anciano de 80 o más Años , Articulación del Codo/fisiología , Femenino , Fracturas Conminutas , Humanos , Masculino , Persona de Mediana Edad , Diseño de Prótesis , Implantación de Prótesis , Radio (Anatomía)/fisiología , Rango del Movimiento Articular , Reproducibilidad de los Resultados , Estudios Retrospectivos , Procedimientos Quirúrgicos Operativos
4.
J BUON ; 19(4): 1096-104, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25536622

RESUMEN

PURPOSE: The results from the published studies on the association between LEP (leptin) genetic polymorphism and cancer risk are conflicting. The common G2548A genetic polymorphism has been reported to be functional and may contribute to genetic susceptibility to cancers. However, the association between LEP G2548A genetic polymorphism and cancer risk remains inconclusive. METHODS: To better understand the role of LEP G2548A genetic polymorphism in global cancer, we conducted this comprehensive meta-analysis encompassing 6860 cases and 7956 controls. RESULTS: Overall, the LEP G2548A genetic polymorphism was associated with higher cancer risk in three genetic models (AA vs GG, AA vs AG/GG, A vs G). In the stratified analysis, there was significant association of LEP G2548A variant with non-Hodgkin's lymphoma (NHL) under homozygous co-dominant model (OR=1.27, 95% CI 1.01-1.60) and additive genetic model (OR=1.14, 95% CI 1.01-1.28). Moreover, a significantly increased cancer risk was found in three genetic models (AA vs GG, AA vs AG/GG, A vs G) among Caucasian population. For Asians, no significant associations were observed in any genetic model tested. CONCLUSIONS: These findings suggest that the LEP G2548A genetic polymorphism may increase the susceptibility of cancers in NHL, especially in the homozygote co-dominant model and the additive genetic model among Caucasian populations. The phenomenon also indicates that the SNP functions as a recessive mutation, which needs to be verified or linked with functional studies.


Asunto(s)
Predisposición Genética a la Enfermedad , Leptina/genética , Neoplasias/genética , Polimorfismo Genético , Estudios de Casos y Controles , Humanos , Riesgo
5.
J Orthop Surg Res ; 9: 106, 2014 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-25370215

RESUMEN

PURPOSE: The electron beam melting (EBM) Ti-6Al-4V material technology has been developed over a short time period. It was introduced through a research to develop Ti-6Al-4V implants for patients, but EBM printed locking compression plates have not been used for clinical implants. The main purpose of this study is to find whether the EBM Ti-6Al-4V plate suit for clinical implants. METHODS: First, we scanned an AO-locking compression plate (LCP) and printed LCP samples using EBM. Next, we evaluated the EBM plate surface roughness through optical microscopy as well as the LCP and EBM plates' mechanical characteristics using the ASTM standard, which is commonly used to test the mechanical properties of bone plates subject to bending. Each sample was examined using a single-cycle four-point bending test and hardness testing to acquire data on bending stiffness, bending strength, bending structural stiffness, and hardness. RESULTS: The results show significant differences in bending stiffness, bending strength, bending structural stiffness, and hardness between the samples using EBM and the original LCP plates. The EBM-printed samples' surface roughness was 0.49 ± 0.02 µm. The mean hardness of the LCP sample was 266.67 HV10 ± 5.8, and the EBM-printed sample mean hardness was 341.1 HV10 ± 1.93. The EBM samples' bending stiffness was 87.67%, which is greater than using the LCP plates'; and the bending strength was 190.7% greater, the bending structural stiffness was 73.2% greater, and the hardness was 27.9% greater. CONCLUSIONS: The results show that the EBM plates' general mechanical strength was significantly greater than the LCP plates. An EBM plate is advantageous for clinical implants because it can be customized with great potential for improvement.


Asunto(s)
Placas Óseas , Impresión Tridimensional , Prótesis e Implantes , Aleaciones , Materiales Biocompatibles/química , Diseño de Equipo , Humanos , Ensayo de Materiales , Titanio
6.
Biomed Rep ; 2(6): 849-854, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25279158

RESUMEN

Previous studies have shown conflicting results between the association of leptin receptor (LEPR) genetic polymorphisms and cancer risk. The frequent LEPR Lys656Asn or Ser343Ser genetic polymorphism has been demonstrated to be functional and may promote genetic susceptibility to cancers. However, the association between the LEPR Lys656Asn or Ser343Ser genetic polymorphism and cancer risk remains to be determined. To improve the understanding of the LEPR Lys656Asn or Ser343Ser genetic polymorphism role in global cancer, a comprehensive meta-analysis was conducted that comprised 2,480 cases and 3,162 controls. The LEPR Lys656Asn or Ser343Ser genetic polymorphism did not significantly affect the cancer risk. In the stratified analysis, there was no significant association of the LEPR Lys656Asn or Ser343Ser variants with any type of cancer under any model. In addition, significantly increased risks were found in the Asian population in heterozygous codominant [odds ratio (OR), 1.24 (1.01-1.53)] and dominant [OR, 1.24 (1.02-1.50)] genetic models. A significantly increased susceptibility to cancer was not found when stratified by study design. There were no significant differences found in genotype method and sample size in cases among the genotypes. These findings indicated a lack of association between LEPR Lys656Asn or Ser343Ser polymorphisms and cancer susceptibility, however, these polymorphisms may increase the cancer susceptibility among the Asian population, particularly in the dominant genetic model. The single-nucleotide polymorphism is also suggested to function as a dominant mutation, which requires verification or association with functional studies.

7.
J BUON ; 19(3): 847-54, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25261678

RESUMEN

PURPOSE: This meta-analysis was conducted to evaluate the association between LEPR K109R (rs1137100) genetic polymorphism and cancer risk. METHODS: To better understand the role of LEPR K109R(rs1137100) genetic polymorphism in global cancer, we conducted this comprehensive meta-analysis encompassing 5819 cases and 8068 controls. RESULTS: Overall, the LEPR K109R(rs1137100) genetic polymorphism did not significantly affect the risk of cancer. In the stratified analysis, significant associations were found between the LEPR K109R(rs1137100) genetic polymorphism and breast cancer under additive genetic model (odds ratio/OR=0.67, 95% CI 0.61-0.73). For prostate cancer, there was no significant association of LEPR K109R(rs1137100) variant with this disease under any model. For lung cancer, there was significant association of LEPR K109R(rs1137100) variant with the disease under heterozygous co-dominant model (OR=0.72, 95% CI 0.55- 0.96), recessive genetic model (OR=0.76, 95% CI 0.61-0.94) and additive genetic model (OR=0.89, 95% CI 0.80-0.99). For gastric cancer, significant association was found in the 3 genetic models (AG vs GG, AA/AG vs GG and A vs G), the ORS (95%CI) being 2.93 (1.25-6.86), 2.93 (1.25-6.86) and 2.25 (1.07-4.72), respectively. Moreover, no significant cancer risk was found in any genetic model among Caucasian and Asian populations. When stratified by study design, no significantly elevated susceptibility to cancer was found among any studies. No significant differences in the genotype method and sample size in cases were found among genotypes. CONCLUSION: These findings suggested that the LEPR K109R(rs1137100) genetic polymorphism may decrease the susceptibility in breast cancer, especially in the additive genetic model. The findings also indicate that single nucleotide polymorphism (SNP) functions as a recessive mutation, which needs to be verified or linked with functional studies.


Asunto(s)
Predisposición Genética a la Enfermedad , Neoplasias/genética , Polimorfismo de Nucleótido Simple , Receptores de Leptina/genética , Humanos , Neoplasias/etiología , Sesgo de Publicación , Riesgo
8.
J BUON ; 19(3): 855-62, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25261679

RESUMEN

PURPOSE: The results from the published studies on the association between LEPR genetic polymorphisms and cancer risk are conflicting. The common LEPR Q223R genetic polymorphism has been reported to be functional and may contribute to genetic susceptibility to cancer. However, the association between LEPR Q223R genetic polymorphism and cancer risk remains inconclusive. METHODS: To better understand the role of LEPR Q223R genetic polymorphism in global cancer, we conducted this comprehensive meta-analysis encompassing 9139 cases and 11282 controls. RESULTS: Overall, the LEPR Q223R genetic polymorphism did not significantly affect the risk of cancer. In the stratified analysis, there was no significant association of LEPR Q223R variant with breast cancer, colorectal cancer and non-Hodgkin's lymphoma (NHL) under any models. Moreover, significantly increased risks were found in Asian and African in all genetic models tested. When stratified by study design, no significantly increased susceptibility to cancer was found among any studies. No significantly differences in sample size in cases were found among genotypes. CONCLUSIONS: These findings suggested lack of association between LEPR Q223R polymorphisms and cancer susceptibility, but the LEPR Q223R genetic polymorphism may increase the susceptibility to cancers in Asian and African individuals. Large, well designed epidemiological studies are needed to validate our findings.


Asunto(s)
Predisposición Genética a la Enfermedad , Neoplasias/genética , Polimorfismo Genético , Receptores de Leptina/genética , Humanos , Neoplasias/etiología , Sesgo de Publicación
9.
Tumour Biol ; 35(8): 8133-41, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24845032

RESUMEN

The results from the published studies on the association between leptin (LEP) genetic polymorphism and cancer risk are conflicting. The common A19G (rs2167270) genetic polymorphism has been reported to be functional and may contribute to genetic susceptibility to cancers. However, the association between LEP A19G (rs2167270) genetic polymorphism and cancer risk remains inconclusive. To better understand the role of LEP A19G (rs2167270) genetic polymorphism in global cancer, we conducted this comprehensive meta-analysis encompassing 5,679 cases and 7,443 controls. Overall, the LEP A19G (rs2167270) genetic polymorphism was associated with lower cancer risk. In the stratified analysis, significant associations were found between the LEP A19G (rs2167270) genetic polymorphism and colorectal cancer and non-Hodgkin's lymphoma. For colorectal cancer, there was no significant association of LEP A19G (rs2167270) variant with this disease under heterozygous codominant model [odds ratio (OR) = 1.11 (0.97-1.27)], dominant genetic model [OR = 1.03 (0.91-1.17)], and additive genetic model [OR = 0.94 (0.86-1.03)]; however, there was a marginal association under homozygous codominant model [OR = 0.80 (0.66-0.97)] and recessive genetic model [OR = 0.75 (0.63-0.90)]. For non-Hodgkin's lymphoma, there was a significant association of LEP A19G (rs2167270) variant with the disease under homozygous codominant model [OR = 0.74 (0.59-0.94)], recessive genetic model [OR = 0.76 (0.61-0.94)], and additive genetic model [OR = 0.89 (0.80-0.99)], but not under heterozygous codominant model [OR = 0.95 (0.82-1.10)] and dominant genetic model [OR = 0.91 (0.79-1.04)]. Moreover, a significantly decreased cancer risk was found in recessive genetic model among Latin American population. When stratified by study design, significantly elevated susceptibility to cancer was not found among any studies. No significantly differences in genotype method and sample size in cases were found among genotypes. These findings suggest that the LEP A19G (rs2167270) genetic polymorphism may decrease the susceptibility to cancers in colorectal cancer and non-Hodgkin's lymphoma, when assuming a homozygote codominant model and a recessive genetic model among Latin American population. The phenomenon also indicates that the SNP functions as a recessive mutation, which needs to be verified or linked with functional studies.


Asunto(s)
Predisposición Genética a la Enfermedad , Leptina/genética , Neoplasias/genética , Polimorfismo Genético , Genotipo , Humanos , Neoplasias/etiología , Sesgo de Publicación , Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...